Arcus Biosciences, Inc.
Clinical trials sponsored by Arcus Biosciences, Inc., explained in plain language.
Biotech developing cancer immunotherapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer drug AB801 enters human safety testing Results expected Nov 2026 (estimated) May already have reported ↗
- New drug AB102 enters first human safety tests Results expected Dec 2026 (estimated) May already have reported ↗
- New hope for advanced stomach cancer: drug cocktails under trial Results expected Jan 2027 (estimated) May already have reported ↗
- Liver health and drug processing: a closer look at casdatifan Results expected May 2027 (estimated) May already have reported ↗
- Double immunotherapy attack shows promise for tough lung cancer Results expected May 2027 (estimated) May already have reported ↗
-
New hope for pancreatic cancer: experimental drug quemliclustat in Late-Stage trial
Disease control OngoingThis Phase 3 trial is testing whether adding an experimental drug called quemliclustat to standard chemotherapy (nab-paclitaxel and gemcitabine) helps people with metastatic pancreatic cancer live longer. About 610 participants who have not yet received treatment for their advanc…
Phase 3 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Double immunotherapy attack shows promise for tough lung cancer
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, zimberelimab and domvanalimab, as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. The study includes 169 participants and aims to see if t…
Phase 2 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New cancer drug AB598 enters first human tests
Disease control OngoingThis early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for advanced stomach cancer: drug cocktails under trial
Disease control OngoingThis study tests whether combining new drugs with or without chemotherapy can safely control advanced stomach, GEJ, or esophageal cancer. About 332 adults with inoperable or metastatic disease will receive different treatment combinations. The goal is to find more effective optio…
Phase 2 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New cancer drug AB801 enters human safety testing
Disease control OngoingThis early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC